Pik3ca-mutated Breast Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2025-11-24
Clinical Trial Update: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC [Phase 2]
This is a Phase II, multicenter, open-label neoadjuvant trial evaluating Inavolisib with Pertuzumab and Trastuzumab plus Nab-paclitaxel for …